Gene Therapy Part Two: Miracle of Medicine & Financial Landmine 💥

Gene therapy can cure diseases that once felt untouchable, but it can also trigger the biggest claim a self-funded employer may ever face. We focus on the hidden costs around the drug, why network contracting matters, and how transparency and preparation protect the health plan when rare cases hit.
• Gene therapy risk for self-funded employers beyond the drug price
• Hidden cost drivers like hospital stays, administration, and follow-up care
• Contract loopholes and vague network terms that inflate total allowed cost
• Why specialized gene therapy networks can run cheaper on average
• The real-world math on how often gene therapy and transplant cases occur
• Preparing for financial earthquakes with better planning and transparency

The urgency that gene therapy is already here, not years away. Let me know if you want to discuss how to get more control of your outstanding risk. 

Music by Alex Lambert.

Transcript

The Real Risk Beyond Price

Why Specialized Networks Cost Less

How Rare Cases Become Earthquakes

Transparency And Contract Terms Matter

Gene Therapy Is Already Here

SPEAKER_00 0:17

Miracle of medicine and a financial landmine. Welcome to another Tuesday morning with Justin. This is part two of our gene therapy episode. I'm Justin Futrel, benefit advisor at TrueNorth Companies. Now, today we're going to continue the conversation about gene therapies, specifically focused on self-funded employers. Here's the part that should make every employer or leader making decisions within a health plan lean forward a little bit. The biggest risk isn't just the price tag of the therapy, it's the other stuff that's wrapped around it. Hospital stays, administration cost, follow-up care, contract loopholes. Many traditional networks have okay pricing on the drug itself, but weak or vague terms on everything else. And those gaps, those gaps exist today because this is a completely new drug to market, a new concept to market, if you will. And so if a plan covers the engine, that Ferrari engine that we talked about last week, but forgets about labor and parts and testing, what's the real cost? This is why network expertise actually matters. I listened to a webinar a couple of weeks ago by uh experts in the gene therapy world, and they highlighted something I thought was counterintuitive. Specialized networks that focus only on gene therapy, cell therapy, and transplants often cost less, not more. On average, about 9% lower allowed cost. That's real money. That's not accounting tricks. And so, as we think about when a single case can cost three or four million dollars, oh, that nine percent becomes hundreds of thousands of dollars. That's the difference between staying within a planned benefit or blowing past stop loss protection. And so the question that I ask is how often does this really happen? Um, and another grounding reality, think about 100,000 people. So Ohio Stadium has 107,000 fans that can fit inside. You might expect three gene or cell therapy cases per year and about 18 transplants. These are rare events. But when they happen, they are financial earthquakes. And earthquakes aren't managed by hope, they're managed by preparation. As we think about transparency and the missing ingredient in healthcare, one of the most refreshing themes from the webinar was transparency. Imagine if before the most expensive claim that ever hits your medical plan in your company's history, you could see the actual contract terms. You knew the fair market value. You understood every component of the cost. That's still rare in healthcare. I know we've talked about it with examples of knee surgeries. How do we find a high-quality, reasonably priced place of care? But why wouldn't we demand it for the most expensive patients we'll ever cover? Here's my closing thought. Gene therapy is not the future. It's already here. It can cure diseases that we once thought were untreatable. It can change lives permanently, and it can completely upend a health plan. The question isn't if employers will face this, it's when. So the real question becomes are we just hoping it won't happen to us? Or are we building plans that are ready when it does? Have a good week.